232 related articles for article (PubMed ID: 17409841)
1. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
[TBL] [Abstract][Full Text] [Related]
3. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Lara PN; Longmate J; Reckamp K; Gitlitz B; Argiris A; Ramalingam S; Belani CP; Mack PC; Lau DH; Koczywas M; Wright JJ; Shepherd FA; Leighl N; Gandara DR
Clin Lung Cancer; 2011 Jan; 12(1):33-7. PubMed ID: 21273177
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Dreicer R; Petrylak D; Agus D; Webb I; Roth B
Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J
Lung Cancer; 2010 Jun; 68(3):420-6. PubMed ID: 19692142
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
[TBL] [Abstract][Full Text] [Related]
16. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
[TBL] [Abstract][Full Text] [Related]
17. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J
Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]